Psychedelics and Meditation: The Contemplative Neuroscience

For most of recorded history, the psychedelic and the contemplative traditions developed in parallel, rarely in conversation. One reached altered states through a molecule taken in ceremony; the other through years of disciplined attention on the cushion. They were treated as opposites — the sudden versus the gradual, the chemical versus the earned. Modern neuroscience has quietly undone that opposition. When researchers put experienced meditators and psilocybin volunteers into the same scanners and asked the same question — what happens to the brain when the sense of a separate self loosens? — they kept finding the same answer, written in the same network. This is the story of that convergence: what meditation does to the brain, what psychedelics do to the brain, why they meet in the same place, and what the first studies combining them actually found.

The Self Has an Address: The Default Mode Network

The brain does not switch off when you stop doing a task. Instead it settles into a signature pattern of activity — the default mode network (DMN) — a set of midline hubs anchored by the medial prefrontal cortex and the posterior cingulate cortex (PCC), with the angular gyrus and medial temporal lobe. First characterized by Marcus Raichle and colleagues in 2001, the DMN is most active during rest, mind-wandering, autobiographical memory, imagining the future, and thinking about oneself and others. It is, in the most useful shorthand, the network of the narrative self — the part of the brain that maintains the running story of “me”: my past, my plans, my standing, my problems.

That story is adaptive. It lets you plan, learn from the past, and model other minds. But it has a cost. An overactive, rigidly self-referential DMN is a recurring feature across the conditions psychedelic medicine targets: rumination in depression, the threat-bound self in anxiety, the craving self in addiction, the trauma-locked self in PTSD. The PCC in particular has emerged, in the work of Judson Brewer and others, as the neural seat of “getting caught up” — of being lost in self-related thought. Both meditation and psychedelics, by very different routes, turn the volume down on this network. That shared target is the thread that runs through everything below.

What Meditation Does to the Brain

The contemplative traditions arrived at the DMN centuries before it had a name. The core instruction of most meditation — return attention, again and again, from the self-story to the present moment — is, in neural terms, a sustained training in down-regulating default mode dominance.

The landmark evidence came from Judson Brewer and colleagues at Yale in 2011. Using fMRI, they compared experienced meditators with matched novices across three styles of practice — concentration, loving-kindness, and choiceless awareness. In experienced meditators, the main DMN hubs — medial prefrontal and posterior cingulate cortices — were relatively deactivated across all three meditation types. Crucially, the meditators also showed stronger coupling between the PCC and regions involved in cognitive control, both during meditation and at rest — a signature consistent with reduced mind-wandering and a standing capacity to notice and release self-referential thought.

This is not a one-study finding. A 2016 meta-analysis of meditation neuroimaging (Fox et al.) found consistent structural and functional differences in meditators across the insula, prefrontal cortex, and the very midline self-processing regions of the DMN. Long-term practice appears to remodel the network gradually: the self-story does not vanish, but its grip weakens, and the practitioner gains the ability to step out of it at will. Meditation, in short, is slow, durable, self-administered neuroplasticity aimed at the architecture of the self.

What Psychedelics Do to the Brain

Psychedelics reach the same network in a single afternoon. Psilocybin — via its active metabolite psilocin — is an agonist at the serotonin 2A (5-HT2A) receptor, which is densely expressed on the deep-layer pyramidal neurons of exactly these high-level association hubs. When Robin Carhart-Harris and colleagues at Imperial College London first imaged the psychedelic brain (PNAS 2012), the headline result was counterintuitive: psilocybin did not light the brain up. It reduced activity and blood flow in the DMN’s central hubs — the mPFC and PCC — and the magnitude of that reduction tracked the intensity of the subjective experience, including the dissolution of the ordinary sense of self.

The deeper model came later. In the REBUS framework (Relaxed Beliefs Under Psychedelics; Carhart-Harris & Friston, 2019), the DMN sits near the top of the brain’s predictive hierarchy, broadcasting the high-level priors — including the prior of being a bounded self — that constrain everything below. By relaxing the precision of those top-down beliefs, psychedelics let lower-level information flow more freely, increase global connectivity between normally segregated networks, and temporarily loosen the self-model. Where meditation gradually trains the DMN to stand down, psychedelics pharmacologically and acutely release its grip. Two roads; one destination.

The Convergence: Two Roads, One Door

Put the two literatures side by side and the overlap is striking. Both meditation and psychedelics reduce the dominance of the default mode network. Both reliably produce, at their depths, the experience the literature calls ego dissolution — the softening or temporary disappearance of the boundary between self and world, described in nearly identical language by advanced meditators and high-dose psychedelic subjects alike. Both shift processing away from narrative, self-referential cognition toward present-centered, embodied awareness. And both, when they work therapeutically, leave people reporting the same kinds of changes: less rumination, more openness, a felt sense of connection, reduced fear.

This convergence has been mapped directly. A 2020 review by Heuschkel and Kuypers cataloged the shared mechanisms — overlapping resting-state connectivity changes, self-dissolution, insight, and neuroplasticity — and argued that meditation and psychedelics are not rivals but complementary tools acting on a common substrate. There appears to be a finite set of ways the brain can release its model of the self, and both technologies find the same door.

The differences matter too, and they are instructive. The meditator’s dissolution is voluntary, gradual, and stable — earned through a trained capacity that persists. The psychedelic dissolution is involuntary, abrupt, and total, then gone in hours. One is a skill; the other is an event. Which is exactly why the most interesting science is about combining them.

When Both Are Used Together

The first rigorous combination study came from Franz Vollenweider’s lab in Zurich. Smigielski, Scheidegger, Kometer, and Vollenweider (NeuroImage, 2019) ran a randomized, double-blind trial in 38 experienced meditators during a five-day mindfulness retreat. Participants received either a single dose of psilocybin or placebo on day four, with fMRI before and after. Psilocybin deepened the meditative experience — producing markedly stronger ego dissolution and self-transcendence during practice — and modulated default mode network connectivity associated with the sense of self. Most importantly, the effects were lasting: at a four-month follow-up, positive changes in psychosocial functioning and attitudes about life correlated with the psilocybin-occasioned shifts in self-processing. The molecule did not replace the practice; it amplified what the practice was already doing, and the practice gave the molecule’s openings somewhere to land.

The complementary result came from Johns Hopkins. Griffiths and colleagues (Journal of Psychopharmacology, 2018) gave 75 healthy adults high-dose psilocybin in the context of a structured program of meditation and spiritual practice, varying the level of support each group received. Psilocybin combined with a committed practice produced enduring increases in altruism, gratitude, forgiveness, interpersonal closeness, and meaning, and decreases in death anxiety — changes still measurable at six months. And the dose of practice mattered: groups with higher support for spiritual practice showed both stronger acute experiences and larger lasting changes. The container shaped the outcome.

Together, these two trials make a single point from two directions. Smigielski shows that adding the molecule to the practice deepens and durably alters the contemplative path. Griffiths shows that adding the practice to the molecule converts a single experience into lasting trait change. The combination is more than the sum of its parts.

Neuroplasticity: The Common Currency

Why should a single dose, or a single retreat, change anything months later? The answer that increasingly unifies both fields is neuroplasticity. Psilocybin promotes rapid structural plasticity — dendritic spine growth in cortical neurons — and recent work (Moliner et al., Nature Neuroscience, 2023) shows psilocin binds the TrkB receptor, the receptor for brain-derived neurotrophic factor (BDNF), as a potent positive allosteric modulator. The acute experience opens a window; the plasticity is what lets new patterns consolidate during it.

Meditation engages the slower side of the same machinery. Sustained practice is associated with increased BDNF and with the gradual structural remodeling documented across the neuroimaging meta-analyses. The emerging synthesis: psychedelics throw open a brief, intense window of plasticity, and contemplative practice is the disciplined activity that shapes what grows through it — and, afterward, the means of keeping the new pattern alive. This is the neuroscientific case for integration, and it is why the field increasingly treats meditation not as an alternative to psychedelic therapy but as its natural complement.

“Training Wheels” — and Its Limits

A popular metaphor frames psychedelics as “training wheels” for meditation: a way to taste, early and vividly, the self-transcendent states that practice otherwise takes years to reach, giving the practitioner a felt target to navigate toward. There is real signal here — many long-term meditators report that a psychedelic experience clarified what their practice had been pointing at, and the Zurich data show psilocybin deepening meditative absorption.

But the metaphor cuts both ways, and honesty requires the other edge. A vivid state is not a trait. The psychedelic shows the destination; only practice builds the legs to walk back there unaided. Without integration — without the slow work that converts insight into habit — the experience can fade into a cherished memory that changes nothing, or worse, into spiritual bypassing. The studies that produced lasting change all paired the molecule with a real container of practice and support. The molecule is the catalyst; the practice is the reaction. Neither the romance of the breakthrough nor the discipline of the cushion is sufficient alone — which may be the oldest lesson both traditions have always taught.

What the Evidence Cannot Yet Tell Us

The convergence is real, but the combination science is young. The two anchor trials are small (38 and 75 participants), conducted in experienced meditators and healthy volunteers — not in clinical populations, where the therapeutic promise lies. We do not yet have large randomized trials testing whether meditation training before and after psychedelic therapy improves outcomes in depression, addiction, or PTSD, though several are now underway. The “shared DMN mechanism” is a powerful organizing frame, but the network is one part of a more complex story; reducing two profound practices to a single network risks oversimplifying both. And individual variation is large — set, setting, temperament, and prior practice all shape what happens. The right posture is the one both traditions counsel: genuine excitement, held with patience, and tested against experience.

The Synthesis

The psychedelic and the contemplative are not opposites and never were. They are two interfaces to the same underlying system — the brain’s model of the self — approached from different directions and at different speeds. Meditation is the slow path: a trained, durable capacity to step out of the self-story at will. Psychedelics are the fast path: an acute, total release that shows, in an afternoon, what the practice is reaching for. The neuroscience suggests they are most powerful not as competitors but as partners — the molecule opening the window, the practice shaping and sustaining what comes through it. Humanity built both of these technologies long before it understood them. We are only now, with the scanner and the trial, beginning to read the instructions we wrote in ceremony and on the cushion millennia ago.